Chu De Saint Etienne — Clinical Trial Site

14 Registered trials

6 Currently recruiting

Organisation

Chu De Saint Etienne

Location

Saint-Etienne Cedex 2, France

Identifier

ORG-100031845

Address

25 Boulevard Pasteur, 42055, France

Departments

CHU de SAINT ETIENNE - Hopital Nord
Gynécologie obstétrique
Gynécologie obstétrique Hôpital Nord
Hématologie
Hepatogastroenterology
Infectious Diseases Department Hôpital Nord-CHU Saint Etienne
médecine vasculaire et thérapeutique
Medical oncology
Oncologie médicale
Oncology
Pneumologie
Service d’hématologie
Service Hématologie

Clinical trials at this site (14)

Search interface

PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 colon carcinoma 5 2024-06-07
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE Recruiting

2022-500974-33-00 acute venous thromboembolism event 5 2023-08-12
Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology. Recruiting

2022-500933-10-00 Preeclampsia during pregnancy 11 2023-08-02
CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting

2022-500295-60-00 Acute Myeloid Leukemia 4 2022-09-15
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO… Ended

2023-504594-20-00 Healthy volunteers 1 2025-01-06
Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended

2022-502369-10-00 Triple negative metastatic breast cancer 5 2023-10-02
IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended

2022-502103-30-00 advanced non-squamous non-small cell lung cancer 4 2023-04-25
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended

2022-501645-70-00 Crohns Disease 5 2020-11-25
Phase I/II study to determine the safety and efficacy of Ribociclib in combination with hormone therapy and hypofractionated radiotherapy in… Ended

2022-501527-24-00 breast cancer 9 2025-01-24
Balloon + Oxytocin versus Oral Misoprostol to Induce labor in case of premature rupture of membranes (PROM) at term in nulliparous Ended

2022-501142-30-00 pregnant women with premature rupture of membranes 6 2023-01-17
LAMSA2020: “A phase II randomized study to assess the efficacy on outcome of Venetoclax combined with Cytarabine versus Idarubicin combined… Ended

2022-502392-37-00 elderly patients (> = 60 years) with Acute Myeloid Leuk 4 2022-05-25